<DOC>
	<DOCNO>NCT01574937</DOCNO>
	<brief_summary>This research study Phase I clinical trial . Phase I clinical trial test safety investigational drug . Phase I study also try define appropriate dose investigational drug use study . `` Investigational '' mean drug still study research doctor try find . It also mean FDA ( U.S. Food Drug Administration ) may approve drug use participant , include people type cancer . In research study , test safety XL184 different dose level . XL184 new study drug , take mouth . Laboratory study show XL184 may prevent tumor growth stop formation blood vessel inside tumor also shrink tumor . This drug use early-stage study also currently study trial . Information research study suggest XL184 may help slow stop tumor growth include prostate cancer . We also take blood urine test look body process drug .</brief_summary>
	<brief_title>XL-184+Abiraterone Post-Chemo CRPC</brief_title>
	<detailed_description>The following procedure perform study . On Day 1 every cycle ( 28 days/4 week ) -The follow undertaken prior initiating study therapy day 1 every subsequent cycle : A medical history , physical exam , performance status , blood test , urine test . Since look high dose study drug administer safely without severe unmanageable side effect participant , everyone participates research study receive dose study drug . The dose get depend number participant enrol study well tolerated dos . We actively monitor condition 30 day come study . If come study side effect monitor condition resolution stabilization side effect</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>CRPC 2 prior chemotherapy regimen Progressive disease CT , MRI bone scan per mRECIST Has recover baseline/CTCAE less equal Grade 1 toxicity relate prior treatment ( except alopecia ) Agree use accept barrier method contraception Cytotoxic chemotherapy within 3 week Prior treatment cabozantinib cMET inhibitor Prior therapy lyase inhibitor Concurrent use hormonal therapy LHRH analogue orchiectomy Received radiation therapy thoracic cavity GI tract within 3 month , bone brain metastasis within 2 week site within 4 week first dose study drug Prior treatment small molecular kinase inhibitor within 2 week study entry Received another investigational product within 28 day prior study entry Active brain metastases epidural disease Requires concomitant treatment therapeutic dos warfarin warfarinrelated agent No uncontrolled significant intercurrent recent illness</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Castration Resistant</keyword>
	<keyword>Post Chemotherapy</keyword>
</DOC>